Skip to main navigation Skip to search Skip to main content

Treatment of gestational diabetes mellitus diagnosed early in pregnancy

  • D. Simmons
  • , J. Immanuel
  • , W. M. Hague
  • , H. Teede
  • , C. J. Nolan
  • , M. J. Peek
  • , J. R. Flack
  • , M. Mclean
  • , V. Wong
  • , E. Hibbert
  • , A. Kautzky-Willer
  • , J. Harreiter
  • , H. Backman
  • , E. Gianatti
  • , A. Sweeting
  • , V. Mohan
  • , J. Enticott
  • , N. W. Cheung
  • , TOBOGM Research Group*

Research output: Contribution to journalArticlepeer-review

277 Citations (Scopus)

Abstract

Abstract Background Whether treatment of gestational diabetes before 20 weeks' gestation improves maternal and infant health is unclear. Methods We randomly assigned, in a 1:1 ratio, women between 4 weeks' and 19 weeks 6 days' gestation who had a risk factor for hyperglycemia and a diagnosis of gestational diabetes (World Health Organization 2013 criteria) to receive immediate treatment for gestational diabetes or deferred or no treatment, depending on the results of a repeat oral glucose-tolerance test [OGTT] at 24 to 28 weeks' gestation (control). The trial included three primary outcomes: a composite of adverse neonatal outcomes (birth at <37 weeks' gestation, birth trauma, birth weight of ≥4500 g, respiratory distress, phototherapy, stillbirth or neonatal death, or shoulder dystocia), pregnancy-related hypertension (preeclampsia, eclampsia, or gestational hypertension), and neonatal lean body mass. Results A total of 802 women underwent randomization; 406 were assigned to the immediate-treatment group and 396 to the control group; follow-up data were available for 793 women (98.9%). An initial OGTT was performed at a mean (±SD) gestation of 15.6±2.5 weeks. An adverse neonatal outcome event occurred in 94 of 378 women (24.9%) in the immediate-treatment group and in 113 of 370 women (30.5%) in the control group (adjusted risk difference, -5.6 percentage points; 95% confidence interval [CI], -10.1 to -1.2). Pregnancy-related hypertension occurred in 40 of 378 women (10.6%) in the immediate-treatment group and in 37 of 372 women (9.9%) in the control group (adjusted risk difference, 0.7 percentage points; 95% CI, -1.6 to 2.9). The mean neonatal lean body mass was 2.86 kg in the immediate-treatment group and 2.91 kg in the control group (adjusted mean difference, -0.04 kg; 95% CI, -0.09 to 0.02). No between-group differences were observed with respect to serious adverse events associated with screening and treatment. Conclusions Immediate treatment of gestational diabetes before 20 weeks' gestation led to a modestly lower incidence of a composite of adverse neonatal outcomes than no immediate treatment; no material differences were observed for pregnancy-related hypertension or neonatal lean body mass.

Original languageEnglish
Pages (from-to)2132-2144
Number of pages13
JournalNew England Journal of Medicine
Volume388
Issue number23
DOIs
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023 Massachusetts Medical Society.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Treatment of gestational diabetes mellitus diagnosed early in pregnancy'. Together they form a unique fingerprint.

Cite this